Efficacy of Infectious Bursal Disease Vaccine in Broiler Chickens Receiving Different Vaccination Programs

Chatchai Sarachai1 Niwat Chansiripornchai2* Jiroj Sasipreeyajan2

Abstract

The objective of this study was to evaluate the efficacy of 3 infectious bursal disease vaccination programs in commercial broiler chickens. One hundred and forty, 1-day-old female broiler chickens were divided into 4 groups of 35 chickens each. Groups 1-3 were vaccinated with infectious bursal disease (IBD) vaccine via oral administration at 1, 1 and 16, and 16-day-old, respectively. Group 4 served as a positive control group. Body weight, sera collection, bursa: body weight (B:BW) ratios and histopathological lesion scores (HLS) were evaluated at 16, 30 and 40-day-old. All the chickens in groups 1 to 4 were challenged with IBD virus at 30-day-old. The survival rate of groups 1-4 were 95.83, 100, 100 and 95.83 percent, respectively. Body weight, B:BW ratios and HLS of each group at 16, 30 and 40-day-old were not significantly different (p>0.05). At 7 and 16-day-old, the average antibody levels of the 1-day-old vaccinated group were significantly lower than the non-vaccinated at 1-day-old group (p<0.05). At 30 and 40-day-old, there was no significant difference in antibodies against IBD virus in all the groups (p>0.05). In conclusion, the vaccination at 1-day-old, 1 and 16-day-old and 16-day-old did not cause adverse effects to body weight, B:BW ratios and HLS.

Keywords: broiler chickens, Infectious bursal disease, vaccination program

1 Department of Food Animal Clinic, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100
2 Avian Health Research Unit, Department of Veterinary Medicine, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330
*Corresponding author E-mail: cniwat@chula.ac.th
Introduction

Infectious bursal disease (IBD) or Gumboro disease is caused by a virus of the Birnaviridae family. The virus has double-stranded RNA. The disease can be found in chickens and other avian species such as ducks, turkeys and ostriches. Only infected chickens show clinical signs but no clinical signs had been found in other infected avian species (Wyeth, 2000). The clinical signs of infected chickens relate to the age and the virulence and the strain of virus. The classical strain of IBD virus (IBDV) belonging to serotype 1, shows the ability to cause clinical disease in infected chickens (Rautenschlein et al., 2003). The clinical signs are depression, reluctance to move, ruffled feathers, loss of appetite, white watery diarrhea and death 2-3 days after the clinical disease has been diagnosed (Chansiripornchai and Sasipreeyajan, 2005). The major symptoms of clinical diseased chickens are dehydration, petechial hemorrhage at the thigh and breast muscles or the juncture between the proventriculus and the ventriculus. Bursa of Fabricius of infected chickens reveals inflammation, edema, hemorrhage or atrophy depending on the course of the infection (Chansiripornchai and Sasipreeyajan, 2009; Sharma et al., 2000). The infection caused by the variant strain of serotype 1 reveals non clinical disease (Elankumaran et al., 2002).

Important methods of IBD prevention and control in the poultry industry are disinfection, biosecurity and vaccination at the appropriate time (Chansiripornchai and Sasipreeyajan, 2009). The commercial vaccines can be divided into 3 groups depending on the virulence of the virus origin; mild, intermediate and intermediate-plus or hot vaccines. The viruses in mild and intermediate vaccine are frequency destroyed by maternal derived antibodies (MDA) in the chicks. Mild and intermediate vaccines will be used in the chicks that have a low level of MDA (Tsukamoto et al., 1995) and the vaccinated chicks should have a booster dose in next 2 weeks to get the optimum antibody protection against IBD infection. On the other hand the intermediate-plus or hot vaccines are suitable for the high MDA chickens (Haddad et al., 1997) because the virus in vaccines can break through the MDA and stimulate the active antibodies against the IBDV in vaccines (Chansiripornchai and Wanasawaeng, 2009). Currently, many IBD vaccines have been developed such as an immune complex vaccine to lessen the neutralizing effect between IBDV and MDA (Chansiripornchai and Sasipreeyajan, 2009; Haddad et al., 1997) or a genetically modified vaccine of the VP2 gene of viral RNA (Chang et al., 2002). The MDA have an affect on the suitable time of the IBD vaccination.
due to the neutralization between the virus in the vaccine and MDA. The objective of this study was to evaluate the efficacy of 3 IBD vaccination programs in commercial broiler chickens.

**Materials and Methods**

**Chickens:** One hundred and forty, 1-day-old female Arbor Acres broiler chickens were obtained from a commercial hatchery (Krungthai, Chonburi, Thailand). The chickens were fed ad libitum (Betagro, Bangkok, Thailand). At the onset of the experiment (16-day-old), there was no statistical significant difference in the average weight of the experimental groups (p>0.05). The guidelines and legislative regulations on the use of animals for scientific purposes of Chulalongkorn University, Bangkok, Thailand were followed as is certified in permission no. 44/2537.

**Vaccines:** The commercial vaccines, Univac-BD® and Bursa Vac® were intermediate and intermediate plus vaccines, respectively, belonging to the classical type of Moulthrop strain. The vaccine was applied according to the manufacture’s recommendation.

**Experimental designs:** One hundred and forty, 1-day-old female broiler chickens were divided into 4 groups (35 each). In group 1, the chickens were vaccinated with IBDV vaccine of the classical type 1, Moulthrop strain (Univac-BD®, Intervet-Schering Plough Animal Health, Nebraska, USA) at 1-day-old by subcutaneous injection. In group 2, the chickens were vaccinated with IBDV vaccine (Univac-BD®) by subcutaneous injection at 1-day-old and also the chickens were vaccinated with IBDV vaccine of the classical type 1, Moulthrop strain (Bursa Vac®, Intervet-Schering Plough Animal Health, Nebraska, USA) by the oral route at 16-day-old. In group 3, the chickens were vaccinated with IBDV vaccine of the classical type 1, Maltrop strain (Bursa Vac®) by the oral route at 16-day-old. Group 4 served as a positive control group and the chickens were not vaccinated but were challenged with IBDV. Sera were collected at 1 day of age for maternal antibody determination. The broilers were weighed and sera were collected at 7, 16, 30 and 40-day-old. The collected sera were tested for IBD antibodies by ELISA (Synbiotics, USA). Feed intakes were measured for the calculation of the feed conversion ratio (FCR). At 30-day-old, all the chickens were challenged orally with IBDV-CU-1, a local strain of very virulent IBDV at a concentration of 4x10^6 embryo infective dose (EID₅₀/bird) for 300 µl/dose (Chansiripornchai and Sasipreeyajan, 2009). Following these vaccinations and challenges, all the chickens were observed for any adverse clinical symptoms (morbidity) and mortality for 10 days.

**Bursa: Body weight ratios and bursal scoring:** Bursa of Fabricius was collected at 16, 30 and 40-day-old for histopathology lesion scoring (HLS) and calculation of the bursa/body weight (B:BW) ratios for 10 chickens in each group. The B:BW ratios were calculated by the bursa of Fabricius weight (g)/ body weight (g) x 1000. Bursal histopathology scoring was performed according to Muskett et al., 1979 following: 0: no damage, 1: mild necrosis in isolated follicles, 2: moderate generalized lymphocyte depletion or isolated follicles with severe depletion, 3: over 50% of follicles with severe lymphocyte depletion, 4: outline of follicles only remaining with few lymphocytes and an increase in connective tissue, cysts and thickened corrugated epithelium, 5: loss of all follicular architecture with fibroplasia.

**Statistical analysis:** FCR and antibody titers were analyzed and compared using Duncan’s multiple range test. HLS was calculated using Kruskal Wallis test. Differences between groups were considered significant at p<0.05. Statistical analysis was calculated by SPSS for Window.

**Results**

**Antibody titers against IBDV:** Antibody titers against IBDV were measured at 7 and 16-day-old. There were significantly different antibody titers (p<0.05) between the non vaccinated chickens at 1 day old and the vaccinated chickens at 1-day-old (Table 1). Before challenge (30-day-old), only one chicken in group 1 showed antibody titer against IBDV but there was no significant difference between groups (p>0.05) (Table 3). Ten days after challenge (40-day-old), all groups of chickens showed rising antibody titers with no significant difference (p>0.05) (Table 4).

**Table 1 Antibodies against IBDV at 7 and 16-day-old (Mean±standard deviation)**

<table>
<thead>
<tr>
<th>Group</th>
<th>Antibodies against IBDV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7-day-old</td>
</tr>
<tr>
<td>Non vaccinated at 1-day-old</td>
<td>4.209±1.262(20/20)*</td>
</tr>
<tr>
<td>Vaccinated at 1-day-old</td>
<td>3.157±1.228(19/20)</td>
</tr>
</tbody>
</table>

Different superscripts mean statistically significant difference (p<0.05)
Number of positive/Total number tested

**Bursal: body weight ratios and histopathological lesion scores:** At 16-day-old, there was no significant difference in the B:BW ratios and HLS between the non vaccinated chickens at 1-day-old and vaccinated chickens at 1-day-old (p>0.05) (Table 2). Before (30-day-old) and after challenge (40-day-old), there was no significant difference in the B:BW ratios and HLS among all groups (p>0.05) (Table 3 and 4). Anyhow, at 30-day-old, all groups of chickens revealed higher B:BW ratios and lower HLS compared to those of 10...
days after challenge. After challenge, the lymphocytes in the bursal follicles were severely decreased by more than 50% and there was more connective tissue and cyst formation on the epithelium of bursal follicles. There was no significant difference in the mortality rate among all groups \((p>0.05)\). One chicken in groups 1 and 4 died; a 95.8% survival rate. By contrast in groups 2 and 3, no chickens died; a 100% survival rate.

**Table 2** Pathological changed of Bursa of Fabricius at 16-day-old (Mean±standard deviation)

<table>
<thead>
<tr>
<th>Group</th>
<th>Pathological changed at 16-day-old</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bursa:Body weight ratio</td>
</tr>
<tr>
<td>Non vaccinated at 1-day-old</td>
<td>2.0923±0.627a</td>
</tr>
<tr>
<td>Vaccinated at 1-day-old</td>
<td>2.2051±0.453a</td>
</tr>
</tbody>
</table>

Different superscripts mean statistically significant difference \((p<0.05)\)

**Table 3** Body weight (gram/bird), B:BW ratios, HLS and antibodies against IBDV at 30-day-old (Mean±standard deviation)

<table>
<thead>
<tr>
<th>Group</th>
<th>Body weight</th>
<th>B:BW</th>
<th>HLS</th>
<th>Antibodies against IBDV</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1,056.18±117.48a</td>
<td>2.74±0.55a</td>
<td>0.1±0.32a</td>
<td>37±165 (1/20)*</td>
</tr>
<tr>
<td>2</td>
<td>1,092.94±98.98a</td>
<td>2.35±0.50a</td>
<td>0.2±0.42a</td>
<td>0 (0/20)</td>
</tr>
<tr>
<td>3</td>
<td>1,073.82±109.32a</td>
<td>2.13±0.61a</td>
<td>0.3±0.48a</td>
<td>0 (0/20)</td>
</tr>
<tr>
<td>4</td>
<td>1,034.41±106.58a</td>
<td>2.16±0.56a</td>
<td>0.5±0.53a</td>
<td>0 (0/20)</td>
</tr>
</tbody>
</table>

Different superscripts mean statistically significant difference \((p<0.05)\)

*Number of positive/Total number tested

**Table 4** Body weight (gram/bird), B:BW ratios, HLS and antibodies against IBDV at 40-day-old (Mean±standard deviation)

<table>
<thead>
<tr>
<th>Group</th>
<th>Body weight</th>
<th>B:BW</th>
<th>HLS</th>
<th>Antibodies against IBDV</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1,363.33±208.05a</td>
<td>0.73±0.18a</td>
<td>4.50±0.69a</td>
<td>3,479±1,107a (10/10)*</td>
</tr>
<tr>
<td>2</td>
<td>1,443.04±108.48a</td>
<td>0.82±0.18a</td>
<td>4.50±0.61a</td>
<td>3,309±537a (10/10)</td>
</tr>
<tr>
<td>3</td>
<td>1,445.22±108.20a</td>
<td>0.81±0.21a</td>
<td>4.25±0.85a</td>
<td>2,576±711a (10/10)</td>
</tr>
<tr>
<td>4</td>
<td>1,276.96±100.92a</td>
<td>0.78±0.16a</td>
<td>4.35±0.75a</td>
<td>3,289±770a (10/10)</td>
</tr>
</tbody>
</table>

Different superscripts mean statistically significant difference \((p<0.05)\)

*Number of positive/Total number tested

### Discussion

The efficacy of IBD vaccination program was related to the level of MDA in the chickens. The MDA of chickens can impede the virus in vaccine infected to the target cells and also reduce the ability of virus in vaccine to stimulate the chicken’s immune system (Chansiripornchai and Wanasawaeng, 2009; Naqi et al., 1983). Anyhow, the MDA is of benefit to IBDV infection in chickens at the age of 1-4 weeks (Al-Natour et al., 2004). Kreider et al. (1991) divided the ELISA titer of the MDA of 1-day-old chickens into 3 level; the low level (<3,000), intermediate level (3,000-5,000) and high level (>6,000). In our experiment, the average MDA of 1-day-old chickens was 6,740±1,282 which was categorized in the high level of MDA. The formula of determining the appropriate age of chickens for IBD vaccination was the mean square root titer of MDA at 1-day-old – the mean square root of target titer/2.82 (Kouwenhoven and van den Bos, 1995). For intermediate plus vaccine, an MDA equal to 334 is the suitable time for vaccination. According to the formula, the appropriate date of intermediate plus vaccination in the experiment is 22-day-old. Therefore, vaccination at 1 or 16-day-old may be affected by MDA resulting in the partial neutralization of the vaccine virus by MDA before the vaccine virus can stimulate chickens’ immunity against IBDV infection. At 30-day-old, no antibody titers against IBDV were detected in groups 2, 3 and 4 and also a low level of antibody against IBDV was detected in group 1. These results may have been caused by the early application of vaccines. At 30-day-old, the antibody against IBDV of chickens vaccinated at 1-day-old was low and did not differ from the control group. Komine et al. (1995) and Knoblich et al. (2000) reported that subcutaneous vaccination of IBDV vaccine at 1-day-old, would not accelerate the reduction of antibodies and antibodies would not be detected at 28-day-old. Also, the antibodies of these chickens would be higher and longer than the antibodies of non vaccinated chickens. Moreover, the detection of antibodies against IBDV after challenge revealed that subcutaneous injection at 1-day-old would stimulate the active immunity of chickens (Haddad et al., 1997).

No difference of B:BW ratios of all groups of chickens at 16 and 30-day-old indicated that subcutaneous vaccination at 1-day-old and oral vaccination at 16-day-old did not effect the
development of bursa of Fabricius. Anyhow, at 40-
day-old (10 days after vaccination), the bursa of all
groups of chickens was reduced and histopathological
damage, indicated that the experimental chickens
were susceptible to the challenge virus. The results
accorded with the no detection of antibodies against
IBDV at 30-day-old (before challenge). Also, at 30-
day-old, no active immunity had been developed due
to the effect of the intermediate or high level of MDA
(Winterfield and Thacker, 1978; Tanimura et al., 1995).
After challenge, there was no significant difference
(p>0.05) in B:W ratios and HLS of all groups because
there was no difference in antibody titers before
challenge. The challenge virus resulted in the high
level of HLS and also the bursal follicles were
destroyed in all groups of vaccination and non
vaccination. Anyhow, the survival rate of chickens in
each group was more than 95%. The heavy breed
chickens reveal lower mortality than the light breed
chickens (Bumstead et al., 1993; Chansiripornchai and
Wanasawaeng, 2009).

From the experiment, the efficacy of IBDV
vaccine in broilers was related to the level of MDA
against IBDV at the vaccination date. Vaccination at 1-
day-old, 1 and 16-day-old and 16-day-old of chickens
that have the ELISA titers of MDA of more than 6,000
at 1-day-old may not be effective enough to elicit the
antibodies at 30-day-old. More research should be
performed. Further study in low or intermediate
MDA chickens should be done. Experiments on virus
protection from challenge and the availability of the
virus in infected organs are required for evaluation of
the efficiency of a vaccination program.

Acknowledgement

This work was basically supported by the
Ratchadaphiseksomphot Endowment Fund,
Chulalongkorn University. We thank Intervet-Shering
Plough and Krung Thai farm to kindly provide the
vaccines and experimental chickens, respectively.

References

L.D. 2004. Effect of different levels of maternally
derived antibodies on protection against
infectious bursal disease virus. Avian Dis. 48(1):
177-182.

Genetic differences in susceptibility of chicken
lines to infection with infectious bursal disease

Chang, H.C., Lin, T.L. and Wu, C.C. 2002. DNA-
mediated vaccination against infectious bursal
disease in chickens. Vaccine. 20(3-4): 328-335.

Chansiripornchai, N. and Sasipreeyajan, J. 2005.
The efficacy of intermediate and intermediate-plus
infectious bursal disease vaccine for the
prevention of infectious bursal disease in

Chansiripornchai, N. and Sasipreeyajan, J. 2009.
Comparison of the efficacy of the immune
complex and conventionally live vaccine in
broilers against infectious bursal disease

Chansiripornchai, N. and Wanasawaeng, W. 2009.
Avian immune system. In: Avian Immune
System and Serum Interpretation. Chansiripornchai, N. (ed), Trionasarn Co. Ltd.,
Bangkok. 27-74.

Pathogenesis and tissue distribution of a variant
strain of infectious bursal disease virus in
commercial broiler chickens. Avian Dis. 46(1):
169-176.

Haddad, E.E., Whitfill, C.E., Avakian, A.P., Ricks,
C.A., Andrews, P.D., Thoma, J.A. and Wakenell,
disease virus immune complex vaccine in broiler

Komine, K., Ohta, H., Fujii, H., Watanabe, Y., Kamata,
S. and Sugiyama, M. 1995. Efficacy of
subcutaneous application of live infectious
bursal disease vaccine in young chickens with

Kouwenhoven, B. and van den Bos, J. 1995. Control of
very virulent infectious bursal disease
(Gumboro disease) in the Netherlands with
more virulent vaccine. Proc. International
Poultry Symposium., Georgia, April 3-4, 29-32.

Knoblich, V.H., Sommer, S.E. and Jackwood, D.J.
2000. Antibody titers to vaccination bursal
disease virus in broiler chickens after one day of
age with infectious bursal disease virus and

Kreider, D.L., Skeeles, J.K., Parsley, M., Newberry,
commercially available enzyme-linked immuno-
sorbent assay system. I. Assay variability. Avian
dis. 35(2): 276-287.

Muskett, J.C., Hopkins, I.G., Edwards, K.R. and
infectious bursal disease vaccine strains: Efficacy
and potential hazard in susceptible and
maternally immune birds. Vet. Rec. 104(15): 332-
334.

antibody and its effect on infectious bursal

Comparative immunopathogenesis of mild,
intermediate, and virulent strain of classic
infectious bursal disease virus. Avian Dis. 47(1):
66-78.

Sharma, J.M., Kim, I.J., Rautenschlein, S. and Yeh,
H.Y. 2000. Infectious bursal disease virus of
chicken: pathogenesis and immunosuppression.

Tanimura, N., Tsukamoto, K., Nakamura, K., Narita,
pathogenicity of infectious bursal disease virus
and viral antigen distribution detected by

Tsukamoto, K., Tanimura, N., Kakita, S., Ota, K.,
of three live vaccines against highly virulent
infectious bursal disease virus in chickens
with or without maternal antibodies. Avian Dis. 39(2):
218-229.